Dynamic42 was founded in spring 2018 in Jena and is currently located at the BioInstrumentezentrum on the Beutenberg Campus. We are a spin-off of the University Hospital Jena. We develop and market novel, three-dimensional, human organ models (so-called organ-on-chip technology) for preclinical research and development as well as for testing novel pharmaceutical products, chemicals and food additives.
Furthermore, we are specialized in immunocompetent organ-on-chip models integrating components of the immune system, which play a significant role in the occurrence of adverse effects of drugs and has been neglected in the industry and in two-dimensional test systems. Our platform enables toxicity screenings and ADMET studies already in preclinical phases on complex microphysiological models of human organs. Hereby, we accompany commercial manufacturers as well as scientists in biomedical research in the design and execution of preclinical studies.
In addition, we develop human disease and infection models in our chip platform, both internally and with external partners – especially in areas where no animal models are available.
Recreating human physiology in vitro for better therapies and disease research without animal experiments.
At Dynamic42, we aim to transform the way drug development and disease research is done. We build human microphysiological systems, to address critical points where pathogens and therapeutic compounds interact with humans. Leveraging our expertise in immune cell integration and perfusion, we aim to build organ models that can address the full complexity of research questions around human biology with a special focus on infection modelling.
Our commitment extends to improving drug development, reducing side effects, and minimizing the risk of translational failure. We want to help our partners to actively reduce animal experimentation, by offering advanced infection and disease models that surpass standard cell culture methods.
Dynamic42 aims to lead in establishing human, physiological organ models, contributing to ethical research practices, and fostering a future where scientific advancements benefit humanity while minimizing the impact on animals.
Ethical and sustainable research without the use of animal models to improve clinical outcomes and disease insights.
Our vision at Dynamic42 is to lead the way in the economical and sustainable development of pharmaceuticals and therapies. We are dedicated to distributing human, microphysiological systems integrated with the latest technologies, aiming to minimize or replace animal experimentation. Upholding ethical values and sustainability in research and development is fundamental to our principles.
Central to our identity is a commitment to the well-being of humans. We strive to enhance drug development and disease research by offering human organ-on-chip models with true physiological complexity. This approach not only increases the safety of newly developed drugs and therapies but also reduces the likelihood of translational failure. Our daily motivation is rooted in the continues development of new applications, as well as the improvement and technological expansion of our platform, to achieve these visionary goals.
We are looking for you! Whether as a researcher or administrative employee – there is still room for you in our team. Take a look at our vacancies now. Didn’t find a suitable position? Then simply apply on your own initiative!
Since April 2023, we have been a proud member of the Thuringia Sustainability Agreement (NAT), which connects sustainably operating companies from Thuringia with each other.
Dynamic42 GmbH is dedicated to reducing animal testing in disease research and drug development and testing. We are pleased to be part of the global community, and we will continue to strengthen our efforts to drive positive change.
Improving people's lives with innovative technologies. This was the goal that Jena-based Dynamic42 had in mind 18 months ago when they launched a project - funded as part of the Sanofi iDEA-iTECH Award Program.
Read MoreThe RUBIN alliance “ATHANA” met for their first strategy workshop one year after the project kicked off in summer last year.
Read MoreWe are excited to welcome Amélie Marie Paillereau to the Dynamic42 science team. Amélie started in April with us for a 12-month-long Master thesis, focusing on perfused breast and pancreatic cancer-on-chip models to study the impact of the tumor microenvironment on immune cell invasion.
Read MoreOnce a quarter, we provide you with exclusive information on current research and interesting articles on organ-on-chip technology, event updates and new product developments in our newsletter.
Subscribe and receive bit-sized tips and insights into the organ-on-chip world!
